U.S. drugmaker Eli Lilly and Co on Wednesday said it would continue a late-stage trial of its experimental breast cancer drug in combination with a widely used treatment even though an independent panel determined the combination therapy failed to meet its interim effectiveness goal.
The independent data monitoring committee recommended the trial continue without modification through the first half of 2017 despite the fact that its interim look at the data suggested the combination treatment was not delaying progression of the disease.
Lilly shares were down 1.2 percent in morning trading.
Leerink analyst Seamus Fernandez said continuation of the study, buy called Monarch 2, viagra would allow Lilly to better understand abemaciclib, which is also being tested in a variety of other trials.
Click here to read more